Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
79,376,583
-
Total 13F shares
-
10,674,595
-
Share change
-
+10,674,595
-
Total reported value
-
$204,526,000
-
Price per share
-
$19.15
-
Number of holders
-
48
-
Value change
-
+$204,526,000
-
Number of buys
-
48
Institutional Holders of Akero Therapeutics, Inc. - COMMON STOCK (AKRO) as of Q2 2019
As of 30 Jun 2019,
Akero Therapeutics, Inc. - COMMON STOCK (AKRO) was held by
48 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
10,674,595 shares.
The largest 10 holders included
venBio Partners LLC, Redmile Group, LLC, Cormorant Asset Management, LP, JANUS HENDERSON GROUP PLC, BVF INC/IL, HILLHOUSE CAPITAL ADVISORS, LTD., BOXER CAPITAL, LLC, WELLINGTON MANAGEMENT GROUP LLP, HILLHOUSE CAPITAL MANAGEMENT, LTD., and Rock Springs Capital Management LP.
This page lists
48
institutional shareholders reporting positions in this security
for the Q2 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.